INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age. ZORYVE cream, 0.15%, is indicated for topical ...

A new study published in the journal of Pediatric Dermatology revealed that treatment with dupilumab achieved effective ...

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

Researchers at Ben-Gurion University of the Negev (BGU) have discovered that a gene long known for shaping the skin's ...

With shares down more than 40% since November, the risk-reward for Nektar Therapeutics has shifted ahead of pivotal clinical ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...

Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with atopic dermatitis (AD).

Experts break down the most important facts about atopic dermatitis on the hands, including risk factors, treatments, and tips for soothing relief. Atopic dermatitis (AD), the most common form of ...

On Saturday, February 14, 2025, from 10am to 1pm and from 3pm to 5pm, in Piazza Garibaldi in Naples, the Dermatology Department of Federico II will provide an excellent team of experts in ...